A new cancer treatment has shown promising results in late-stage trials. This treatment is for melanoma, a serious skin cancer. It involves a customized approach, using a patient's specific tumor mutations to create a tailored therapy.

The treatment combines an existing immunotherapy drug with a personalized mRNA therapy. Details about the trial are limited, but the companies involved plan to share more information at medical meetings and with regulators.

Further details about the trial and treatment are expected to be released by the companies, which will provide more insight into this potential breakthrough in cancer treatment.